Latest news with #healthcareinnovation
Globe and Mail
2 days ago
- Business
- Globe and Mail
3 Best Growth Stocks to Buy in June
Growth investors have had to work harder than usual to find winners in 2025. With the S&P 500 essentially flat year to date amid President Trump's global trade reset and persistent inflation concerns, the easy gains of prior years have evaporated. Yet beneath the surface, a select group of companies continues to deliver explosive growth driven by transformative trends in artificial intelligence (AI), healthcare innovation, and next-generation technologies. The divergence between market leaders and laggards has rarely been more pronounced. While the average stock treads water, companies with genuine competitive advantages and exposure to secular growth themes are posting triple-digit gains. From AI infrastructure providers handling the computational demands of large language models to biotech firms developing breakthrough obesity treatments, the opportunities for outsized returns remain -- if you know where to look. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Here are three growth stocks with the catalysts, financials, and market positioning to potentially deliver significant gains in the months ahead. AI infrastructure juggernaut CoreWeave (NASDAQ: CRWV) has emerged as the picks-and-shovels play of the AI revolution. The company operates specialized data centers built from the ground up for GPU-intensive computing, providing the infrastructure that powers large language models and generative AI applications. Shares have rocketed 185% year to date, driven by explosive growth and massive customer wins. The company's Q1 2025 revenue surged 420% year over year to $981.6 million, while its $11.9 billion contract with OpenAI validates its position as the go-to infrastructure provider for AI leaders. With a $25.9 billion revenue backlog and management guiding for $4.9 billion to $5.1 billion in 2025 revenue, the growth runway remains substantial. The main risk is the company's hefty losses. CoreWeave posted a $314.6 million net loss in Q1, driven by $264 million in interest expenses. Furthermore, capital expenditures are expected to reach $20 billion to $23 billion in 2025 alone. Another key risk is that customer concentration remains high, with Microsoft representing 62% of 2024 revenue. However, for investors who believe AI adoption is still in the early innings, CoreWeave offers one of the purest plays on the trend. Biotech with blockbuster potential Viking Therapeutics (NASDAQ: VKTX) stands out as a contrarian opportunity. Despite shares falling 33% this year, the clinical-stage biotech has multiple shots on goal with its pipeline of metabolic and endocrine therapies. The key catalyst ahead is data from the Phase 2 VENTURE trial for VK2735, the company's oral obesity drug candidate. Top-line results are expected in the second half of this year. Meanwhile, the company is preparing to launch Phase 3 trials for its subcutaneous VK2735 formulation later this quarter, positioning the drug for potential regulatory approval within a few years. This dual-track approach, consisting of oral and injectable formulations, maximizes the commercial opportunity in the competitive obesity market. Viking reported cash and investments of approximately $852 million at the end of Q1 2025, providing runway through multiple clinical readouts without dilution. Wall Street remains bullish with a median price target of $90, representing over 230% upside from current levels. For biotech investors comfortable with clinical risk, the recent pullback creates an attractive entry point ahead of potentially game-changing data. Power semiconductor innovator Navitas Semiconductor (NASDAQ: NVTS) is pioneering next-generation power semiconductors using gallium nitride (GaN) and silicon carbide (SiC) technologies. These materials enable faster, more efficient, and smaller power systems -- critical for everything from EV chargers to data center power supplies. Shares have gained 42.8% this year despite Q1 2025 revenue of just $14 million, down from $23.2 million a year ago. The catalyst? Nvidia recently selected Navitas to collaborate on its next-generation 800V HVDC architecture for "Kyber" rack-scale systems that will power future GPUs. This collaboration positions Navitas at the heart of AI infrastructure buildout, with its GaN and SiC technologies enabling power delivery from grid to GPU for megawatt-scale AI data centers. The company has $450 million in design wins from 2024 that should convert to revenue starting late 2025, with the majority hitting in 2026. Additional wins include a 12 kW AI data center power platform and the industry's first GaN EV on-board charger with Changan. With over 250 million GaN units shipped to date, Navitas has proven its game-changing technology is ready for prime time, making its stock a compelling growth play right now. Should you invest $1,000 in CoreWeave right now? Before you buy stock in CoreWeave, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and CoreWeave wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!* Now, it's worth noting Stock Advisor 's total average return is979% — a market-crushing outperformance compared to171%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of May 19, 2025
Arab News
5 days ago
- General
- Arab News
Saudi Arabia unveils robotic surgery program ahead of Hajj 2025
MAKKAH: Saudi Arabia's Minister of Health Fahad Al-Jalajel inaugurated a surgical robotics program at King Abdullah Medical City in Makkah as part of the Kingdom's preparations to ensure world-class healthcare during Hajj 2025. The robotic surgery unit, operated by Saudi surgeons, will enable minimally invasive procedures in areas such as thoracic surgery, urology, and oncology. The technology is expected to shorten recovery time, reduce surgical risks, and significantly enhance the quality of patient care, the Ministry of Health said in press release on Thursday. 'This project represents a major leap in our healthcare capabilities during the Hajj season,' said Al-Jalajel. 'We are harnessing innovation to ensure that pilgrims receive the highest level of medical care, in line with the Vision 2030 goals of improving health services and integrating advanced technologies,' he added. In addition to the robotic surgery unit, the minister unveiled a new PET-CT scanner, the first of its kind in the ministry's facilities in the Western Region. The advanced imaging device will provide precise diagnostics for conditions such as cancer, cardiovascular diseases, and neurological disorders, and will support the early detection and treatment of critical cases. The initiatives are part of a broader national effort to raise the standards of healthcare provided to pilgrims. The Kingdom has already launched multilingual health awareness campaigns, deployed mobile infectious disease units, and increased medical capacity across the holy sites. With more than 50,000 healthcare professionals and advanced technologies in place, Saudi Arabia is aiming to make Hajj 2025 not only spiritually fulfilling but also medically safe and secure for all pilgrims.
Arab News
5 days ago
- General
- Arab News
Saudi Arabia unveils robotic surgery and PET-CT scanner to boost Hajj healthcare services
RIYADH: Saudi Arabia has introduced robotic surgery at King Abdullah Medical City in Makkah, the Kingdom's Ministry of Health said on Thursday. The new robotic system marks a major advancement in healthcare services provided to Hajj pilgrims and will support procedures in thoracic surgery, urology, and oncology, enabling greater surgical precision and faster recovery for patients. The initiative is part of the Ministry of Health's efforts to leverage technology to improve the quality and efficiency of care delivered during the annual pilgrimage. The hospital has also launched the first-ever PET-CT scanner within the ministry's hospitals in the western region. The diagnostic tool allows for early detection of cancers, cardiovascular diseases, and neurological disorders, significantly enhancing diagnostic capabilities. These developments are in line with the Kingdom's Vision 2030, which emphasizes innovation and excellence in healthcare, the ministry said. The expansion of high-tech medical services during Hajj reflects Saudi Arabia's continued commitment to ensuring the health and safety of pilgrims from around the world.
Associated Press
7 days ago
- Business
- Associated Press
New study led by Horizon and supported by Roche Canada delivers cancer treatment in the comfort of a patient's home
MISSISSAUGA, ON, May 28, 2025 /CNW/ - For the first time in Canada, a patient has received cancer immunotherapy by subcutaneous (under the skin) injection in their home, thanks to an innovative research initiative by Horizon Health Network (Horizon), in collaboration with Roche Canada, the New Brunswick Extra-Mural Program, and ResearchNB, and with support from Vitalité Health Network. The project originated with a research study led by Horizon medical oncologists Dr. Mahmoud Abdelsalam, Dr. Luisa Galvis and Dr. James Michael whereby New Brunswick patients diagnosed with certain types of lung cancer receive Health Canada-authorized subcutaneous cancer immunotherapy at home, administered by nurses from Medavie's New Brunswick Extra-Mural Program. The initiative was formally announced by the New Brunswick delegation during the annual BIO International Convention in June 2024 in San Diego, California, and the first treatment milestone occurred in New Brunswick this past March. 'This trial marks a turning point in lung cancer care—bringing treatment from the hospital to patients' homes, where they are most comfortable,' said Dr. Abdelsalam, who served as principal investigator of the research initiative. 'We are proud to lead this Canadian-first trial from New Brunswick, showing that innovation in health care can start right here at home, improving the quality of care for New Brunswickers.' The study was initially designed to bring care closer to communities. However, Dr. Abdelsalam challenged the team to go further — to 'close the last mile' by delivering modern cancer therapies directly to patients' homes. Previously, patients travelled to hospital-based infusion centres for intravenous cancer treatments, often spending at least 30 to 60 minutes per visit. The new subcutaneous injection reduces treatment time to about seven minutes, offering a more convenient, less invasive option that minimizes disruptions to patients' daily life, reduces the strain on health care providers, and increases capacity in the health care system. 'The reality is, if patients must leave their communities, take time off work, arrange childcare or organize transportation, it disrupts their lives significantly,' said Jennifer Sheils, Horizon's Vice-President of Strategy, Transformation and Chief Innovation Officer. 'They occupy IV therapy hospital chairs, require nursing and pharmacy resources and often face the challenge of travelling home while feeling unwell. These impacts extend beyond the treatment day and can affect their overall well-being and financial stability.' As industry partners like Roche Canada introduce new therapies that move beyond traditional IV delivery, Horizon is leading the way in rethinking cancer care by putting patient needs first and helping to build a more efficient, responsive health care system. Key benefits of an injection (subcutaneous) formulation to the patient, compared to traditional IV formulations, can include: 'The challenges faced by healthcare systems in Canada have never been greater. Horizon Health's outstanding leadership shows that transforming this system is possible. By thinking differently about how we collaborate, we can deliver better care to patients and their families. We are very proud to partner with Horizon Health on this project, which will help ensure all patients have access to the best innovation in healthcare, when they need it - a key part of Roche's vision,' said Dr. Dan Edgcumbe, Vice President of Medical and Regulatory Affairs at Roche Pharma Canada. 'This experience will help us all better understand the full value of healthcare innovation to provide more accessible, flexible care options while expanding healthcare system capacity.' Through this partnership, patients now have the choice to receive injections at home, reducing disruption to their daily lives and alleviating pressures on hospital resources. This innovative model empowers patients while supporting a more efficient and patient-centered health care system. This approach is also expected to improve health system operations by reducing pressure on infusion clinics, increasing treatment capacity, optimizing workflow and potentially lowering overall costs per patient. Horizon hopes health care systems across Canada will look to this example as a model for accelerating patient-centred innovation. Advancing research and adopting new approaches to care delivery will be critical to building a more sustainable health care system. Horizon is committed to fostering a culture of improving patient outcomes through research and innovation initiatives like this one. Each year, Horizon Research Services supports approximately 117 clinical trials for new treatments and solutions, along with nearly 307 investigator-led studies advancing health care knowledge and practice. Patients interested in participating in this study, referred to as Subcutaneous Treatment with Immunotherapy for Cancer Patients at Home, or STITCH-01, or another Horizon research study are encouraged to complete a research application form, available on the Horizon website. About Horizon Health Network Horizon Health Network is the largest regional health authority – and one of the largest employers – in New Brunswick, and the second-largest health authority in Atlantic Canada. Our leadership and health care providers are experts in diverse areas of health and community services and provide services to a half a million people. The organization has an annual budget of approximately $1.4 billion and has more than 14,000 employees, 1,242 physicians and 1,300 volunteers, as well as 17 foundations and 16 auxiliaries and alumnae organizations. About Roche Canada At Roche Canada, patients and science are at the heart of everything we do. Our passion for science and our commitment to relentlessly pursuing the impossible for patients have made us one of the world's leading pharmaceutical, in-vitro diagnostics, and diabetes care management companies. With our combined strength in diagnostics and pharmaceuticals, we're driving healthcare forward, while ensuring we deliver meaningful benefits for patients and sustainable healthcare systems. We are committed to creating a world where we all have more time with the people we love. And we're adding our expertise in new areas, such as artificial intelligence, real world data collection and analysis and collaborating with many different sectors and industries. Having the courage to reinvent ourselves and question the status quo is what patients and healthcare systems expect from Roche - and our commitment is as strong today as it was on the first day of our Canadian journey in 1931. Today, Roche Canada employs nearly 2,000 people at its offices in Mississauga, Ontario, in Laval, Quebec, and across the country from coast to coast to coast. For more information, please visit or follow Roche Canada on LinkedIn. About ResearchNB ResearchNB is the province's research and innovation enabler. With offices in Fredericton, Saint John and Moncton, it provides New Brunswick's research sector with critical leadership and support including advocacy, initial funding, connections to potential partners, and the translation of science into economic opportunities. Projects developed in partnership with ResearchNB help New Brunswickers to thrive through research that leads to new, innovative business practices and products. About New Brunswick Extra-Mural Program The New Brunswick Extra-Mural Program (EMP) delivers primary health care services to New Brunswickers of all ages in their homes and communities. EMP, known by many as the 'hospital without walls', includes a team of over 850 professionals who provide quality home health care services to eligible residents when their needs can be met safely in the community. EMP operates on a client and family centered model with a focus on building and maintaining partnerships with clients and their families, physicians, agencies, departments and other service providers to best meet patient needs. SOURCE Hoffmann-La Roche Limited (Roche Canada)
National Post
7 days ago
- Business
- National Post
WELL Health Reports HEALWELL AI and WELLSTAR Subsidiaries Are Selected for Canada Health Infoway's Vendor Innovation Program
Article content WELL Health is pleased to report that HEALWELL's wholly owned subsidiary Intrahealth, non-wholly owned subsidiary Pentavere along with WELLSTAR's subsidiary OceanMD have been selected by Canada Health Infoway as recipients for the 2025 Vendor Innovation Program. The Vendor Innovation Program is designed to accelerate the development, clinical implementation and adoption of interoperability in healthcare settings across Canada. Intrahealth, Pentavere and OceanMD are engaging in projects that accelerate the adoption of interoperability by improving data quality, enhancing care coordination, and expanding access to standardized, actionable health information for patients and clinicians across Canada. Their projects were selected not only based on technical merit, but for their demonstrated potential to deliver real, lasting impact on Canada's digital health priorities. Three out of the eight winners of the Vendor Innovation Program are from the WELL Health and HEALWELL families. This achievement highlights the group's leadership and innovation in the digital health sector, further solidifying its role in transforming healthcare in Canada. Article content Article content VANCOUVER, British Columbia & TORONTO — WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) ('WELL' or the 'Company'), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that HEALWELL AI Inc. (TSX: AIDX, OTCQX: HWAIF)(' HEALWELL '), and WELLSTAR Technologies Inc. (' WELLSTAR '), subsidiaries, Intrahealth Systems Limited ('Intrahealth'), (non-wholly owned) Pentavere Research Group Inc. ('Pentavere'), and 2355581 Ontario Inc. dba OceanMD ('OceanMD'), have been selected by Canada Health Infoway (' Infoway '), as recipients of the 2025 Vendor Innovation Program (VIP), recognizing integrated, forward-looking solutions that will help advance connected care, improve patient access to their health information, and enhance care coordination across the Canadian health system. Article content Infoway's Vendor Innovation Program (VIP) is designed to accelerate the development and clinical implementation of real-world interoperability innovations that are aligned with the Shared Pan-Canadian Interoperability Roadmap. The program empowers selected vendors to develop and implement innovations that accelerate the adoption of interoperability. This year's winning projects exemplify how innovation can accelerate the adoption of interoperability by improving data quality, enhancing care coordination, and expanding access to standardized, actionable health information for patients and clinicians. Article content 'The Vendor Innovation Program is a critical component in mobilizing Canada's digital health industry,' says Abhi Kalra, Executive Vice President, Connected Care at Canada Health Infoway. 'By supporting the implementation of real-world solutions in clinical settings, we are helping to demonstrate what's possible when innovation is aligned with national priorities and focused on the needs of patients and care teams.' Article content Dr. Alexander Dobranowski, CEO of HEALWELL, said, 'Intrahealth and Pentavere's recognition through the Vendor Innovation Program demonstrates the tremendous impact HEALWELL companies are having in the digital health landscape. Both companies are at the forefront of transforming healthcare delivery with innovative solutions that enhance data-driven care coordination, streamline workflows, and empower clinicians to deliver better patient outcomes. We remain committed to improving patient care and supporting healthcare providers with actionable insights, while also focusing on addressing the needs of underserved and rural communities, where our technology can make the most meaningful difference.' Article content Amir Javidan, CEO of WELLSTAR, said, 'We are incredibly proud to see OceanMD, as part of WELLSTAR, recognized for its innovation in improving healthcare outcomes through digital technologies. This recognition is a testament to the exceptional work our team is doing in transforming patient care, and we are excited to see the impact this will have in clinical settings across Canada. In total, WELL Health and HEALWELL companies have earned significant recognition in this prestigious program, with three out of the eight winners coming from the WELL Health family. This achievement highlights our leadership and innovation in the digital health sector, further solidifying our role in transforming healthcare across Canada.' Article content Selected from more than 40 applications across the country, the 2025 VIP cohort reflects the breadth of Canada's healthcare landscape, including solutions targeting primary care, acute care, and Indigenous and rural communities. The three recipient projects from the WELL Health family are as follows: Article content Pentavere: Integrating its DARWEN™ AI system with EMRs to generate clinician-facing patient summaries, reducing chart review time and improving provider efficiency. OceanMD: Enhancing its eReferral system with open APIs and AI automation to streamline referral workflows and support real-time clinical decision-making. Intrahealth: Developing standardized FHIR-based tools to enable seamless, accurate transfer of full patient records between EMR systems across Canada. Article content These projects were selected not only for their technical merit, but for their demonstrated potential to deliver real, lasting impact on Canada's digital health priorities. These three initiatives will be deployed in live clinical environments, across Alberta, British Columbia, Ontario, New Brunswick, and Nova Scotia, providing tangible value to patients, clinicians, and health system leaders. Article content WELL HEALTH TECHNOLOGIES CORP. Article content Per: 'Hamed Shahbazi' Hamed Shahbazi Chief Executive Officer, Chairman and Director WELL Health Technologies Inc. Article content WELL's mission is to tech-enable healthcare providers. We do this by developing the best technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. WELL's comprehensive healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. WELL's solutions enable more than 42,000 healthcare providers between the US and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 210 clinics supporting primary care, specialized care, and diagnostic services. In the United States WELL's solutions are focused on specialized markets such as the gastrointestinal market, women's health, primary care, and mental health. WELL is publicly traded on the Toronto Stock Exchange under the symbol 'WELL' and on the OTC Exchange under the symbol 'WHTCF'. To learn more about the Company, please visit: Article content Canada Health Infoway (Infoway) is an independent, not-for-profit organization funded by the federal government and accountable to its Board of Directors and Members of the Corporation (Canada's 14 federal, provincial and territorial deputy ministers of health). Infoway is led by a team of seasoned professionals who are specialists in their respective fields, including health care, administration, information technology and privacy. Learn more online at Article content Certain statements in this press release, constitute 'forward-looking information' and 'forward looking statements' (collectively, 'forward looking statements') within the meaning of applicable Canadian securities laws, including the Company's, WELLSTAR's, and HEALWELL's plan to further develop and deploy technologies in clinical environments. Forward-looking statements are often, but not always, identified by words or phrases such as 'building', 'scaling', 'to become', 'opportunity', 'burgeoning', 'continue to', 'focus', 'believe', 'pursue', 'entering', 'growth', 'expect', 'intend', 'anticipate' or variations of such words and phrases or statements that certain future conditions, actions, events or results 'will', 'may', 'could', 'would', 'should', 'might' or 'can' be taken, occur or be achieved, or the negative of any of these terms. Forward-looking statements are necessarily based upon management's perceptions of historical trends, current conditions and expected future developments, as well as a number of specific factors and assumptions that, while considered reasonable by the Company, HEALWELL, and WELLSTAR as of the date of such statements, are outside of their control and are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward looking statements contained in this press release are based on various assumptions, including, but not limited to: WELL's, HEALWELL's and WELLSTAR's ability to further develop the technologies identified above, and identifying customers interested in deploying such technologies in a clinical environment; the continued adoption of the software, tools and solutions created by WELL, WELLSTAR and HEALWELL; sufficiency of working capital and access to financing; WELL's, WELLSTAR's and HEALWELL's ability to comply with applicable laws and regulations; technologies working as intended or at all; trends in customer growth and the adoption of new technologies in the industry; and that the risk factors noted below, collectively, do not have a material impact on HEALWELL's business, operations, revenues and/or results. By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections, or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. Article content Known and unknown risk factors, many of which are beyond the control of WELL and HEALWELL, could cause the actual results of WELL and HEALWELL to differ materially from the results, performance, achievements, or developments expressed or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed under the section entitled 'Risk Factors' in WELL's most recent annual information form dated April 15, 2025, which is available under WELL's SEDAR+ profile, and HEALWELL's most recent annual information form dated March 31, 2025, which is available under HEALWELL's SEDAR+ profile. The risk factors are not intended to represent a complete list of the factors that could affect WELL and HEALWELL and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. WELL and HEALWELL disclaim any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements. Article content Article content Article content Contacts Article content For more information: Article content Article content Article content
